Moderna D
D
MRNA
246.890
USD
-3.92
(-1.56%)
Pre Open·252.480USD+5.590(+2.26%)
Last updated: · Delayed 15 min
Moderna current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
Moderna's current ratio is 3.62: current assets of 7.34B USD against current liabilities of 2.03B USD due within a year.
- Today
- 3.62
- Average, 5 years
- 3.15
- Low, 5 years
- 1.76
- High, 5 years
- 4.39
Current ratio = current assets ÷ current liabilities = 7.34B ÷ 2.03B = 3.62
Current ratio
Total current assets
Total current liabilities
Current assets over current liabilities at each quarter end: above 1, what falls due within a year is covered by what turns into cash within a year.
Current ratio by year and by quarter
| Fiscal year | Period ending | Current ratio | Total current assets | Total current liabilities |
|---|---|---|---|---|
| Today | 3.62 | 7.34B | 2.03B | |
| FY2025 | 31 Dec 2025 | 3.29 | 6.54B | 1.99B |
| FY2024 | 31 Dec 2024 | 3.67 | 8.10B | 2.21B |
| FY2023 | 31 Dec 2023 | 3.42 | 10.33B | 3.02B |
| FY2022 | 31 Dec 2022 | 2.73 | 13.43B | 4.92B |
| FY2021 | 31 Dec 2021 | 1.76 | 16.07B | 9.13B |
| FY2020 | 31 Dec 2020 | 1.43 | 6.30B | 4.39B |
| FY2019 | 31 Dec 2019 | 7.89 | 1.13B | 143.12M |
| FY2018 | 31 Dec 2018 | 7.02 | 1.56B | 222.80M |
| FY2017 | 31 Dec 2017 | 4.09 | 783.22M | 191.46M |
| FY2016 | 31 Dec 2016 | 6.68 | 1.09B | 162.80M |
| Quarter | Period ending | Current ratio | Total current assets | Total current liabilities |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 3.62 | 7.34B | 2.03B |
| Q2 FY2026 | 30 Jun 2026 | 2.29 | 5.82B | 2.53B |
| Q1 FY2026 | 31 Mar 2026 | 2.41 | 5.77B | 2.40B |
| Q4 FY2025 | 31 Dec 2025 | 3.29 | 6.54B | 1.99B |
| Q3 FY2025 | 30 Sept 2025 | 3.93 | 6.60B | 1.68B |
| Q2 FY2025 | 30 Jun 2025 | 3.93 | 6.17B | 1.57B |
| Q1 FY2025 | 31 Mar 2025 | 4.22 | 6.77B | 1.60B |
| Q4 FY2024 | 31 Dec 2024 | 3.67 | 8.10B | 2.21B |
| Q3 FY2024 | 30 Sept 2024 | 4.39 | 9.67B | 2.20B |
| Q2 FY2024 | 30 Jun 2024 | 4.09 | 9.66B | 2.36B |
| Q1 FY2024 | 31 Mar 2024 | 4.03 | 9.60B | 2.38B |
| Q4 FY2023 | 31 Dec 2023 | 3.42 | 10.33B | 3.02B |
| Q3 FY2023 | 30 Sept 2023 | 2.46 | 10.80B | 4.39B |
| Q2 FY2023 | 30 Jun 2023 | 3.39 | 10.60B | 3.12B |
| Q1 FY2023 | 31 Mar 2023 | 3.46 | 12.12B | 3.50B |
| Q4 FY2022 | 31 Dec 2022 | 2.73 | 13.43B | 4.92B |
| Q3 FY2022 | 30 Sept 2022 | 2.10 | 14.30B | 6.81B |
| Q2 FY2022 | 30 Jun 2022 | 1.99 | 13.56B | 6.81B |
| Q1 FY2022 | 31 Mar 2022 | 1.77 | 16.35B | 9.24B |
| Q4 FY2021 | 31 Dec 2021 | 1.76 | 16.07B | 9.13B |
| Q3 FY2021 | 30 Sept 2021 | 1.35 | 13.43B | 9.96B |
| Q2 FY2021 | 30 Jun 2021 | 1.24 | 10.97B | 8.84B |
| Q1 FY2021 | 31 Mar 2021 | 1.39 | 11.70B | 8.44B |
| Q4 FY2020 | 31 Dec 2020 | 1.43 | 6.30B | 4.39B |
| Q3 FY2020 | 30 Sept 2020 | 2.43 | 3.58B | 1.47B |
| Q2 FY2020 | 30 Jun 2020 | 17.30 | 2.80B | 161.65M |
| Q1 FY2020 | 31 Mar 2020 | 9.29 | 1.25B | 134.58M |
| Q4 FY2019 | 31 Dec 2019 | 7.89 | 1.13B | 143.12M |
| Q3 FY2019 | 30 Sept 2019 | 7.40 | 1.09B | 147.84M |
| Q2 FY2019 | 30 Jun 2019 | 6.77 | 1.10B | 161.99M |
| Q1 FY2019 | 31 Mar 2019 | 7.17 | 1.14B | 159.16M |
| Q4 FY2018 | 31 Dec 2018 | 7.02 | 1.56B | 222.80M |
| Q3 FY2018 | 30 Sept 2018 | 6.00 | 1.12B | 186.42M |
| Q2 FY2018 | 30 Jun 2018 | 5.81 | 1.16B | 200.02M |
| Q1 FY2018 | 31 Mar 2018 | — | 756.03M | 0.00 |
| Q4 FY2017 | 31 Dec 2017 | 4.09 | 783.22M | 191.46M |
| Q3 FY2017 | 30 Sept 2017 | — | — | — |
| Q2 FY2017 | 30 Jun 2017 | — | — | — |
| Q1 FY2017 | 31 Mar 2017 | — | 1.06B | 0.00 |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:Market cap,P/S ratio,ROE (return on equity),Debt to equity,All ratios
Common questions about Moderna's current ratio
Source: Financial Modeling Prep